Britain backs GSK's gene therapy for 'bubble boy' syndrome
(Reuters) - GlaxoSmithKline's gene therapy for the so-called "bubble boy" disease was approved by Britain's healthcare cost watchdog NICE, despite a price tag of almost 600,000 euros ($700,000). Gene therapy is designed to deliver a one-off cure for the patient and drugmakers are typically asking a hefty price that is comparable to the combined costs of alternative life-long treatment. "Costing 594,000 euros, the treatment is usually given once only and the effects are thought to be life-long," it added. The draft guidance marks the first time NICE has applied its new cost effectiveness limits for treatments for very rare conditions.